126 related articles for article (PubMed ID: 22111941)
1. Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.
van Beuge MM; Poelstra K; Prakash J
Expert Opin Drug Deliv; 2012 Jan; 9(1):59-70. PubMed ID: 22111941
[TBL] [Abstract][Full Text] [Related]
2. Protein kinases as targets for cancer treatment.
Giamas G; Stebbing J; Vorgias CE; Knippschild U
Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
[TBL] [Abstract][Full Text] [Related]
3. Renal targeting of kinase inhibitors.
Dolman ME; Fretz MM; Segers GJ; Lacombe M; Prakash J; Storm G; Hennink WE; Kok RJ
Int J Pharm; 2008 Dec; 364(2):249-57. PubMed ID: 18550305
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
Ghigo A; Morello F; Perino A; Hirsch E
Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
Dai Y
Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
Dasanu CA; Padmanabhan P; Clark BA; Do C
Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
[TBL] [Abstract][Full Text] [Related]
8. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
9. Strategies to overcome resistance to targeted protein kinase inhibitors.
Daub H; Specht K; Ullrich A
Nat Rev Drug Discov; 2004 Dec; 3(12):1001-10. PubMed ID: 15573099
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase inhibitors: breakthrough medicines and the next generation.
Sawyer TK; Wu JC; Sawyer JR; English JM
Expert Opin Investig Drugs; 2013 Jun; 22(6):675-8. PubMed ID: 23705633
[TBL] [Abstract][Full Text] [Related]
11. PIM1 kinase as a target for cancer therapy.
Merkel AL; Meggers E; Ocker M
Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
[TBL] [Abstract][Full Text] [Related]
12. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
Sehon CA; Wang GZ; Viet AQ; Goodman KB; Dowdell SE; Elkins PA; Semus SF; Evans C; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
J Med Chem; 2008 Nov; 51(21):6631-4. PubMed ID: 18842034
[TBL] [Abstract][Full Text] [Related]
13. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
Bagrodia S; Smeal T; Abraham RT
Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
16. Targeting Polo-like kinase in cancer therapy.
Degenhardt Y; Lampkin T
Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
[TBL] [Abstract][Full Text] [Related]
17. Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
[TBL] [Abstract][Full Text] [Related]
18. Targeting protein kinases.
Melnikova I; Golden J
Nat Rev Drug Discov; 2004 Dec; 3(12):993-4. PubMed ID: 15645605
[No Abstract] [Full Text] [Related]
19. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features.
Fang Z; Grütter C; Rauh D
ACS Chem Biol; 2013 Jan; 8(1):58-70. PubMed ID: 23249378
[TBL] [Abstract][Full Text] [Related]
20. [Losmapimod: a novel drug against cardiovascular diseases?].
Dewenter M; Vettel C; El-Armouche A
Dtsch Med Wochenschr; 2013 Jan; 138(1-2):39-42. PubMed ID: 23250695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
